obesity drug news today glp-1 september 22 2025 The Access Gap: Mapping Who Can Actually Afford America's Miracle Weight-Loss Drugs What to Know About New

The AWARD-7 trial, which is notable for its exclusive focus on patients with moderate-to-severe chronic kidney disease, demonstrated that dulaglutide users, particularly those simultaneously using ACE inhibitors or angiotensin receptor blockers, exhibited a substantially less eGFR decline compared to insulin glargine users

We expect future studies on vision loss associated with Ozempic use to be an important part of the Ozempic vision loss lawsuits

This is exactly the kind of nuance that headline-level reporting misses but protocol-level planning demands

IGFBP1 is recognized for inhibiting IGF-1 bioactivity (26)

Treatment potential of the GLP-1 receptor agonists in type 2 diabetes mellitus: a review

The dual action of Tirzepatide effectively reduces caloric intake while improving glucose metabolism, which explains why the SURMOUNT-1 trial data showed up to a 22.5% mean weight reduction at the 72-week mark